Our results demonstrate that a combination of parameters readily accessible in the clinic–low platelet count (<150/nL), ISS stage III, WHO > 1, and age >60 years–consistently predicted risk of severe infection and severe infection/death in patients treated with concurrent, modern induction therapies, including quadruplets with an anti-CD38 mAb. Here, CD38 is linked to infection.